Jessica Merrill

Jessica Merrill

Senior Editor

Brooklyn, NY

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest from Jessica Merrill

GSK’s Blujepa Brings Innovation To The Antibiotic Space

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’

The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval

Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.

Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned

The company’s Immunovant announced positive data from a Phase III trial in myasthenia gravis but the focus is on next-generation drug IMVT-1402.

Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III

A Phase III trial testing the protein degrader in breast cancer met the primary endpoint and showed an efficacy benefit only in the subgroup of ESR1 mutant patients, not the full population.

Trevi Gets A Clap On The Back For Chronic Cough Data

A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.